BOULDER, Colo.--(BUSINESS WIRE)--Aug. 14, 2012--
(NYSE: COV), a leading global provider of healthcare products and
recognized innovator in patient monitoring and respiratory care devices,
today announced its support for The Joint Commission’s recent Sentinel
Alert recommendations for the “Safe
use of opioids in hospitals.”
Opioids, frequently given to patients for pain management, may be
associated with increased risk for dangerous complications from
respiratory depression. The Joint Commission’s newly published
recommendations address these risks by urging hospitals to establish
procedures for accurate pain-level assessment as well as continuous
monitoring of patients’ blood oxygenation and ventilation through pulse
oximetry and capnography.
“These recommendations represent an important milestone that should
enhance patient safety in hospitals nationwide,” said Scott Kelley,
M.D., Chief Medical Officer, Respiratory and Monitoring Solutions,
Covidien. “In particular, capnography, which monitors adequacy of
ventilation through exhaled carbon dioxide, provides an early indication
of hypoventilation or respiratory distress, and represents one option
for enabling clinicians to detect and address these health threats
The Joint Commission’s guidelines align with recommendations issued by
the Anesthesia Patient Safety Foundation (APSF) and the Institute for
Safe Medication Practices (ISMP) calling for continuous monitoring of
ventilation of hospitalized patients receiving opioids postoperatively.
Covidien is a global leader in capnography devices, offers
market-leading respiratory function technologies and a complete
portfolio of monitoring solutions that can help hospitals meet The Joint
Commission, APSF and ISMP recommendations. The Company’s technologies
include Integrated Pulmonary Index™ and a recently expanded suite of
Nellcor™ pulse oximetry solutions.
Covidien also helps hospitals comply with patient safety standards by
partnering with healthcare providers to offer education and training.
For example, when capnography is implemented, Covidien experts work with
hospital staff to ensure they understand the clinical need for
capnography as well as how to interpret capnography monitor readings to
best support clinical decision making.
“Covidien’s ongoing partnerships with healthcare providers to develop
training and education around issues impacting patient safety,
demonstrate our ongoing commitment to delivering medical solutions that
meet the highest standards of care,” said Robert J. White, President,
Respiratory & Monitoring Solutions, Covidien.
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien manufactures,
distributes and services a diverse range of industry-leading product
lines in three segments: Medical Devices, Pharmaceuticals and Medical
Supplies. With 2011 revenue of $11.6 billion, Covidien has 43,000
employees worldwide in more than 65 countries, and its products are sold
in over 140 countries. Please visit www.covidien.com
to learn more about our business.
Rhonda Luniak, 303-305-2263
Lannum, CFA, 508-452-4343